Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

Gianfranco Ferraccioli; Carlo.A. Scirè; Roberto Caporali; Piercarlo Sarzi-Puttini; Bruno Frediani; Manuela Di Franco; Angela Tincani; Luigi Sinigaglia; Paolo Sfriso; Rosella Tirri; Emanuela Bellis; Giovanni Delsante; Giovanni Porru; Fausto Salafi; Dilia Giuggioli; Maurizio Rossini; Monica Todoerti; Laura Bazzichi; Marcello Govoni; Roberto Gerli; Roberto Raschetti; Giovanni Minisola; Carlomaurizio Montecucco; Silvano Todesco

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

Gianfranco Ferraccioli, Carlo.A. Scirè, Roberto Caporali, Piercarlo Sarzi-Puttini, Bruno Frediani, Manuela Di Franco, Angela Tincani, Luigi Sinigaglia, Paolo Sfriso, Rosella Tirri, Emanuela Bellis, Giovanni Delsante, Giovanni Porru, Fausto Salafi, Dilia Giuggioli, Maurizio Rossini, Monica Todoerti, Laura Bazzichi, Marcello Govoni, Roberto GerliRoberto Raschetti, Giovanni Minisola, Carlomaurizio Montecucco, Silvano Todesco

Facoltà di Medicina e Chirurgia "A.Gemelli"

Risultato della ricerca: Contributo in rivista › Articolo in rivista

37 Citazioni (Scopus)

Abstract

To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.

Lingua originale	English
pagine (da-a)	857-863
Numero di pagine	7
Rivista	CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Volume	31
Stato di pubblicazione	Pubblicato - 2013

Keywords

rheumatoid arthritis
therapy

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint Entra nei temi di ricerca di 'Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database'. Insieme formano una fingerprint unica.

Cita questo

Ferraccioli, G., Scirè, C. A., Caporali, R., Sarzi-Puttini, P., Frediani, B., Di Franco, M., Tincani, A., Sinigaglia, L., Sfriso, P., Tirri, R., Bellis, E., Delsante, G., Porru, G., Salafi, F., Giuggioli, D., Rossini, M., Todoerti, M., Bazzichi, L., Govoni, M., ... Todesco, S. (2013). Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 31, 857-863.

Ferraccioli, Gianfranco ; Scirè, Carlo.A. ; Caporali, Roberto ; Sarzi-Puttini, Piercarlo ; Frediani, Bruno ; Di Franco, Manuela ; Tincani, Angela ; Sinigaglia, Luigi ; Sfriso, Paolo ; Tirri, Rosella ; Bellis, Emanuela ; Delsante, Giovanni ; Porru, Giovanni ; Salafi, Fausto ; Giuggioli, Dilia ; Rossini, Maurizio ; Todoerti, Monica ; Bazzichi, Laura ; Govoni, Marcello ; Gerli, Roberto ; Raschetti, Roberto ; Minisola, Giovanni ; Montecucco, Carlomaurizio ; Todesco, Silvano. / Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2013 ; Vol. 31. pagg. 857-863.

@article{c962454d5a92482aa674c3de922126cb,

title = "Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database",

abstract = "To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.",

keywords = "rheumatoid arthritis, therapy, rheumatoid arthritis, therapy",

author = "Gianfranco Ferraccioli and Carlo.A. Scir{\`e} and Roberto Caporali and Piercarlo Sarzi-Puttini and Bruno Frediani and {Di Franco}, Manuela and Angela Tincani and Luigi Sinigaglia and Paolo Sfriso and Rosella Tirri and Emanuela Bellis and Giovanni Delsante and Giovanni Porru and Fausto Salafi and Dilia Giuggioli and Maurizio Rossini and Monica Todoerti and Laura Bazzichi and Marcello Govoni and Roberto Gerli and Roberto Raschetti and Giovanni Minisola and Carlomaurizio Montecucco and Silvano Todesco",

year = "2013",

language = "English",

volume = "31",

pages = "857--863",

journal = "CLINICAL AND EXPERIMENTAL RHEUMATOLOGY",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology:Via S Maria 31, I 56126 Pisa Italy:011 39 050 40124, EMAIL: info@clinexprhematol.org, INTERNET: http://www.clinexprhematol.org, Fax: 011 39 050 502299",

}

Ferraccioli, G, Scirè, CA, Caporali, R, Sarzi-Puttini, P, Frediani, B, Di Franco, M, Tincani, A, Sinigaglia, L, Sfriso, P, Tirri, R, Bellis, E, Delsante, G, Porru, G, Salafi, F, Giuggioli, D, Rossini, M, Todoerti, M, Bazzichi, L, Govoni, M, Gerli, R, Raschetti, R, Minisola, G, Montecucco, C & Todesco, S 2013, 'Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database', CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol. 31, pagg. 857-863.

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. / Ferraccioli, Gianfranco; Scirè, Carlo.A.; Caporali, Roberto; Sarzi-Puttini, Piercarlo; Frediani, Bruno; Di Franco, Manuela; Tincani, Angela; Sinigaglia, Luigi; Sfriso, Paolo; Tirri, Rosella; Bellis, Emanuela; Delsante, Giovanni; Porru, Giovanni; Salafi, Fausto; Giuggioli, Dilia; Rossini, Maurizio; Todoerti, Monica; Bazzichi, Laura; Govoni, Marcello; Gerli, Roberto; Raschetti, Roberto; Minisola, Giovanni; Montecucco, Carlomaurizio; Todesco, Silvano.

In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, Vol. 31, 2013, pag. 857-863.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

AU - Ferraccioli, Gianfranco

AU - Scirè, Carlo.A.

AU - Caporali, Roberto

AU - Sarzi-Puttini, Piercarlo

AU - Frediani, Bruno

AU - Di Franco, Manuela

AU - Tincani, Angela

AU - Sinigaglia, Luigi

AU - Sfriso, Paolo

AU - Tirri, Rosella

AU - Bellis, Emanuela

AU - Delsante, Giovanni

AU - Porru, Giovanni

AU - Salafi, Fausto

AU - Giuggioli, Dilia

AU - Rossini, Maurizio

AU - Todoerti, Monica

AU - Bazzichi, Laura

AU - Govoni, Marcello

AU - Gerli, Roberto

AU - Raschetti, Roberto

AU - Minisola, Giovanni

AU - Montecucco, Carlomaurizio

AU - Todesco, Silvano

PY - 2013

Y1 - 2013

N2 - To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.

AB - To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.

KW - rheumatoid arthritis

KW - therapy

KW - rheumatoid arthritis

KW - therapy

UR - http://hdl.handle.net/10807/53998

M3 - Article

VL - 31

SP - 857

EP - 863

JO - CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

JF - CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

SN - 0392-856X

ER -